Dopamine, a neurotransmitter for motor function, is implicated in dyskinetic illness.
Movement disorders are significant adverse drug effects (ADEs) of several psychotropic
drugs with anti-dopamine action. Buspirone, an azapirone, is a partial agonist to
serotonin 5HT1A. The medication's therapeutic advantages relate to its interaction
with these receptors. Buspirone also inhibits dopamine receptors, which could be linked
to the medication's unusual side effects in individuals who are predisposed to them.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the American Medical Directors AssociationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
